NTVO - jaargang 21, nummer 2, mei 2024
dr. E. van Mastrigt , dr. E. de Vos-Kerkhof , dr. J. van der Lugt
Dit is een journalscan van het artikel “The type II RAF inhibitor tovorafenib in relapsed/refractory pediatric low-grade glioma: the phase 2 FIREFLY-1 trial” met commentaar voor de Nederlandse klinische praktijk.
(NED TIJDSCHR ONCOL 2024;21:91–3)
Lees verder
Naar boven
To provide the best experiences, we and our partners use technologies like cookies to store and/or access device information. Consenting to these technologies will allow us and our partners to process personal data such as browsing behavior or unique IDs on this site and show (non-) personalized ads. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Click below to consent to the above or make granular choices. Your choices will be applied to this site only. You can change your settings at any time, including withdrawing your consent, by using the toggles on the Cookie Policy, or by clicking on the manage consent button at the bottom of the screen.
